BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, May 2, 2026
Home » Topics » Infection » Coronavirus

Coronavirus
Coronavirus RSS Feed RSS

Red blood cells and coronavirus

Expert panel links AZ vaccine to blood clots, though exact cause remains unknown

Aug. 11, 2021
By Nuala Moran
LONDON – Stopping people under 40 from receiving Astrazeneca plc’s COVID-19 vaccine has put an end to the serious blood-clotting syndrome associated with the product, with no new cases in the U.K. for the past four weeks, according to an expert panel of hematologists.
Read More

Regulatory actions for Aug. 11, 2021

Aug. 11, 2021
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Akouos, Belief, Dermavant, Fibrogen, GW, Innocare, Lantern, Merck, Phasebio, Reata, Roivant, SFJ.
Read More

Other news to note for Aug. 11, 2021

Aug. 11, 2021
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Adaptive, Advaxis, Algernon, Alphabet, Bio-Thera, Clene, Curebase, Dyadic, Hoth, Humacyte, Imbrium, Kaleido, Lumen, Merz, Mindset, Moderna, Neximmune, Nouscom, Orizuru, Protagonist, Purdue, Puretech, Q Biomed, Sab, Second Genome, Skye, Sorrento, Therapeutic Solutions, Tryp, Vensica, Veraxa, Wesana, Zealand.
Read More

In the clinic for Aug. 11, 2021

Aug. 11, 2021
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Apollomics, Athersys, Avacta, Azurrx, Cohbar, Crinetics, Cytoagents, Flexion, Fulcrum, Goldfinch, Grunenthal, Healios, Heparegenix, I-Mab, Immvira, IMV, In8bio, Inflarx, Novaliq, Nrx, Point, Pulmatrix, Reata, Retrotope, Rezolute, Sinovac, Summit, Trevena.
Read More
Coronavac product packaging

Sinovac reports positive data on COVID-19 booster, loss of antibodies within months

Aug. 10, 2021
By Sergio Held
Sinovac Biotech Ltd. said booster shots of its Coronavac vaccine against SARS-CoV-2 induce strong immune responses in adult and elderly populations following a considerable loss of antibodies six to eight months after completing the current two-dose regimen.
Read More

SK Bioscience advances first South Korean-developed COVID-19 vaccine to late-stage testing

Aug. 10, 2021
By Gina Lee
SK Bioscience Ltd. has won approval from the South Korean Ministry of Food and Drug Safety (MFDS) to begin a phase III trial for its COVID-19 vaccine candidate GBP-510, making the recombinant protein antigen vaccine the first domestically developed candidate to make it to late-stage testing. “We aim to begin the phase III trials within August and to have the data ready by early 2022,” a company spokesman told BioWorld.
Read More

HHS settles whistleblower complaint with former BARDA director

Aug. 10, 2021
By Mari Serebrov
Rick Bright, who filed a whistleblower complaint last year against the U.S. Department of Health and Human Services (HHS) after he was removed from his position as director of the Biomedical Advanced Research and Development Authority (BARDA), reached an undisclosed settlement with HHS, the U.S. Office of Special Counsel reported Aug. 9.
Read More
Single strand RNA

Low-profile mRNA developer Greenlight going public in $1.5B SPAC merger

Aug. 10, 2021
By Lee Landenberger
MRNA’s the thing and special purpose acquisition company (SPAC) Environmental Impact Acquisition Corp. is following as it will merge with privately held mRNA-developer Greenlight Biosciences Inc.
Read More

Regulatory actions for Aug. 10, 2021

Aug. 10, 2021
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Phase Scientific.
Read More

Other news to note for Aug. 10, 2021

Aug. 10, 2021
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Abbott, Asia Molecular Diagnostic Laboratory, Cardinal Health, China Biotech Services Holding, Empiramed, Fitbit, Fujifilm, Fujifilm Irvine Scientific, Happify Health, Life Whisperer, Lifescan, Oncxerna Therapeutics, Pillar Biosciences, Presagen, Pyramid Innovation, Qiagen, Quidel, Statlab Medical Products.
Read More
Previous 1 2 … 200 201 202 203 204 205 206 207 208 … 552 553 Next

Popular Stories

  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 28, 2026
  • Chinabio 2026 partnering

    Chinese biotechs gain leverage as partners in dealmaking

    BioWorld
    China’s biotech ecosystem has crossed an inflection point, and Chinese biotechs are gaining leverage in dealmaking, executives from multinational companies said...
  • AI generated image for researcher developing antisense oligonucleotides

    Bio Korea 2026 kicks off with spotlight on oligonucleotides

    BioWorld
    Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
  • Roche identifies new TREM2 agonists

    BioWorld Science
    F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have prepared and tested new compounds acting as triggering receptor expressed on myeloid cells 2 (TREM2)...
  • Silhouette of head, brain

    Plasticity, properly parsed, provides psychiatric platform

    BioWorld
    If Benjamin Braddock, of The Graduate fame, were a young neuroscientist in the 21st century instead of a liberal arts graduate in 1967, the advice he received...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing